Karyopharm Therapeutics

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Karyopharm reports robust revenue growth and strategic clinical advancements

Karyopharm Therapeutics demonstrated strong performance in revenue growth and clinical pipeline advancements, positioning them for continued success in 2023.
Strategic strengths in product portfolio, leadership, and innovation align well with opportunities in accelerating growth and exploring novel treatment approaches.
Challenges in differentiation, data updates, and dose optimization require focused strategies to overcome obstacles and drive sustainable growth.
Overall, Karyopharm's focus on patient outcomes, strategic expansion, and upcoming milestones indicate a positive trajectory for the company.

Karyopharm Therapeutics navigates revenue challenges while advancing pipeline innovations

Karyopharm Therapeutics faced revenue challenges due to PAP usage and discounts but showcased strong demand for XPOVIO and promising pipeline progress.
The company's financial stability was supported by expense reductions and total revenue of $38.7 million for Q1 2023.
Opportunities lie in commercial expansions, Phase III data advancements, and strategic product development efforts, positioning Karyopharm for future growth and innovation.

Karyopharm Therapeutics excels in Q2, eyes $2B peak revenues

Karyopharm Therapeutics showcased strong financial performance, strategic workforce reductions, and progress in pivotal Phase III trials during the Q2 earnings call. The company's focus on advancing novel SINE compounds and maintaining financial strength positions them well for future growth and value creation.

Karyopharm Therapeutics reports robust Q3 earnings and highlights growth prospects

Karyopharm Therapeutics showcased strong financial performance with revenue of $36 million and emphasized growth potential.
Promising Phase III trial data for myelofibrosis and endometrial cancer positions selinexor as a treatment paradigm changer.
Challenges include PAP impact from foundation closures, but opportunities lie in novel drug combinations and growth strategies.

Karyopharm meets revenue targets, eyes transformative outcomes in trials

Karyopharm Therapeutics delivered on revenue targets, showcasing strong performance and promising trial results in key indications.
While facing challenges in academic settings and financial obligations, the company's strategic strengths and growth opportunities position it well for the future.
With a focus on advancing Phase III trials, leveraging IP advantages, and exploring new treatment avenues, Karyopharm aims for continued innovation and market expansion.
Overall, Karyopharm's Q4 2023 Earnings Call reflects a balanced outlook with a solid foundation for growth and value creation in the biopharmaceutical sector.

Karyopharm Therapeutics reports strong Q1 performance and strategic refinancing

Karyopharm Therapeutics' Q1 2024 earnings call highlighted robust performance, strategic refinancing, and promising late-stage pipeline developments. While facing challenges in financial clarity and trial progress, the company is well-positioned to capitalize on growth opportunities through biomarker-driven patient selection and combination therapies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

This company's repurposed cancer drug might help patients with severe COVID-19.

Should You Buy Stock Now in This New Coronavirus Drug Developer?

Does Karyopharm Therapeutics (KPTI) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Karyopharm Therapeutics (KPTI) a Strong Momentum Stock: Buy Now?

Supernus Pharmaceuticals

These two underrated biotech stocks have the potential to soar.

Your 2 Top Profit Opportunities in 2020

Karyopharm (KPTI) doses the first patient in a phase II study evaluating the low dose of its drug Xpovio (selinexor) to treat hospitalized patients with severe COVID-19 infection. Shares up.

Karyopharm Starts Dosing With Selinexor for Coronavirus Infection

NEWTON, Mass., April  20, 2020  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced dosing of the first patient in a randomized Phase 2 clinical study evaluating low dose oral selinexor in hospitalized patients with severe COVID-19. This global study is expected to enroll approximately 230 patients at clinical sites in the U.S., Europe, and Israel.  Selinexor is an oral selective inhibitor of nuclear export (SINE) compound which blocks the cellular protein XPO1 which is involved in both the replication of SARS-CoV-2, the virus that causes COVID-19, and in the inflammatory response to the virus.

Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19

Gilead Sciences

Intercept Pharma

Intra-Cellular Therapies

Ovid Therapeutics

The coronavirus pandemic has cast the spotlight on the world of biotechnology stocks as researchers search for not only a vaccine, but for additional drugs that can help in the treatment of the virus.

RBC Has 5 Biotech Stocks Rated Outperform With Up to 100% Upside Potential

NEWTON, Mass., April  01, 2020  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 161,500 shares of Karyopharm’s common stock to 22 newly-hired employees, with a grant date of March 31, 2020.  The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Karyopharm Therapeutics - Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm (KPTI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Karyopharm (KPTI): Strong Industry, Solid Earnings Estimate Revisions

NEWTON, Mass., March  17, 2020  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted a stock option to purchase 151,200 shares of Karyopharm’s common stock to John Demaree, the Company’s newly-appointed Chief Commercial Officer, with a grant date of March 16, 2020.  The stock option was granted as an inducement material to Mr. Demaree entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $16.50 per share, the closing price of Karyopharm’s common stock on the Nasdaq Global Select Market on March 16, 2020. The stock option vests over four years, with 25% of the original number of shares underlying the stock option vesting on the one-year anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to Mr. Demaree’s continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. In addition, the stock option will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a “change in control event,” Mr. Demaree’s employment is terminated for “good reason” by Mr. Demaree or terminated without “cause” by Karyopharm (as such terms are defined in the stock option agreement).

Karyopharm Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

NEWTON, Mass., March  12, 2020  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the appointment of John Demaree as Chief Commercial Officer. In this role, Mr. Demaree will lead Karyopharm’s commercial strategy and operations, including the continued commercialization of oral XPOVIO® (selinexor), the Company’s first-in-class, Selective Inhibitor of Nuclear Export (SINE) compound.

Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer

NEWTON, Mass., March  09, 2020  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 119,500 shares of Karyopharm’s common stock to seventeen newly-hired employees, with a grant date of March 5, 2020. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Karyopharm Therapeutics  - Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., March  06, 2020  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the closing of its previously announced registered underwritten public offering and the exercise in full of the underwriters’ option to purchase additional shares. 7,187,500 shares of the Company’s common stock at a price to the public of $24.00 per share were issued and sold in the offering, which includes 937,500 shares issued upon the exercise of the underwriters’ option to purchase additional shares. The gross proceeds to Karyopharm from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be $172.5 million.

Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

Karyopharm Therapeutics: All Systems Go

NEWTON, Mass., March  03, 2020  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the pricing of its previously announced registered underwritten public offering of 6,250,000 shares of its common stock  at a price to the public of $24.00 per share. The gross proceeds to Karyopharm from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be $150.0 million. The offering is expected to close on or about March 6, 2020, subject to customary closing conditions. In addition, Karyopharm has granted the underwriters a 30-day option to purchase up to 937,500 additional shares of its common stock. J.P. Morgan, Morgan Stanley and Jefferies are acting as joint book-running managers for the offering. RBC Capital Markets, Baird and H.C. Wainwright & Co. are acting as co-managers for the offering.

Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock

Shares of Karyopharm Therapeutics Inc. KPTI, +63.59% soared 65% in trading on Monday after the drugmaker said an experimental combination treatment for multiple myeloma met its primary endpoint in a late-stage clinical trial.

Karyopharm's stock jumps on trial results for multiple myeloma combo candidate

Karyopharm Therapeutics unveiled promising results for a late-stage cancer treatment on Monday. The news prodded KPTI stock to rocket higher and break out of a consolidation at 20.19.

This Biotech Stock Broke Out As A Cancer Drug 'Transforms' Its Story

Current Executive Vice President and Chief Executive Officer of Ipsen North America, and former Vice President and General Manager of Oncology at Amgen, Inc.; Brings Wealth of Leadership and Global Strategic Experience Current Executive Vice President and Chief Executive Officer of Ipsen North America, and former Vice President and General Manager of Oncology at Amgen, Inc.; Brings Wealth of Leadership and Global Strategic Experience

Karyopharm Appoints Richard Paulson to its Board of Directors

Investors need to pay close attention to Karyopharm (KPTI) stock based on the movements in the options market lately.

Do Options Traders Know Something About Karyopharm (KPTI) Stock We Don't?

This cancer-drug maker has a novel medicine with the possibility for extraordinary growth.

Here's Why Karyopharm Therapeutics Has a Unique Growth Opportunity

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares made a handy gain on Wednesday after the firm secured a key U.S.

This FDA Approval of Karyopharm’s Lymphoma Treatment Could Be Huge

For long-term investors, the risk/reward profile on KPTI still seems attractive.

Karyopharm Therapeutics: Pullback Is Overdone

Karyopharm Therapeutics Inc. (KPTI) CEO Michael Kauffman on Q4 2019 Results - Earnings Call Transcript

NEWTON, Mass. and PETAH TIKVA, Israel, Feb.  11, 2020  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, and Promedico, a member of the Neopharm Group, today announced their entry into an exclusive distribution agreement for the commercialization of XPOVIO® (selinexor), Karyopharm’s lead SINE compound, in Israel and the Palestinian Authority.

Karyopharm and Promedico, a Member of the Neopharm Group, Enter into an Exclusive Distribution Agreement to Commercialize XPOVIO® (Selinexor) in Israel

NEWTON, Mass., Feb.  03, 2020  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 87,000 shares of Karyopharm’s common stock to sixteen newly-hired employees, with a grant date of January 31, 2020.  The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4).

News for Karyopharm Therapeutics Stock (KPTI)